Top Markets
Coin of the day
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
株式のランク #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
株価
$0.0416118
時価総額
$12.78M
変化(1日)
1.72%
変化(1年)
-22.01%
AU
取引 Noxopharm Limited (NOX)

カテゴリー

Noxopharm Limited(NOX)の営業利益率
March 2026 時点の営業利益率 TTM: -532.32%
Noxopharm Limited の最新の財務報告と株価によると、現在の営業利益率(TTM)は -532.32% です。2024 年末時点では -313.92% でした。
Noxopharm Limited の営業利益率の履歴(2016 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -532.32% 55.59%
2025 -342.14% 8.99%
2024 -313.92% 13.69%
2023 -276.12% -1.43%
2022 -280.14% 7.54%
2021 -260.50% 31.83%
2020 -197.61% -52.69%
2019 -417.69% -63.54%
2018 -1,145.69% -55.34%
2017 -2,565.11% 0.00%
2016 0.00% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
41.30% -100.08%
DK
35.45% -100.07%
US
24.95% -100.05%
US
25.32% -100.05%
BE
25.72% -100.05%
AU
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。